Valbenazine

EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Retrieved on: 
Giovedì, Ottobre 26, 2023

BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Key Points: 
  • BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
    The issuer is solely responsible for the content of this announcement.
  • The rise in bond yields weighed heavily on biotech stocks as well as the stock market in general.
  • BB Biotech benefited from the dollar's appreciation, but it was also exposed to the sustained selling pressure on equity markets.
  • BB Biotech traded within a narrow range during the third quarter, closing slightly higher at CHF 41.35 per share.

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology

Retrieved on: 
Venerdì, Maggio 19, 2023

SAN DIEGO, May 19, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that the complete study results from its Phase 3 KINECT™-HD study investigating valbenazine for the treatment of chorea associated with Huntington's disease (HD) has been published in The Lancet Neurology online edition and will appear in the June 2023 print issue. The study met pre-defined primary and secondary endpoints of improvement in chorea severity and global impression of change, demonstrating a reduction in chorea symptoms associated with HD and improvement of overall chorea severity as noticed by clinicians and patients, with improvement seen as early as Week 2 of the initial dose in the 12-week study.

Key Points: 
  • "The KINECT-HD study data demonstrated statistically significant improvement in chorea associated with HD as compared with placebo.
  • The safety profile for participants with chorea associated with HD was consistent with the known safety profile of valbenazine.
  • The KINECT-HD study marked the first-ever implementation of the Huntington's Disease Health Index (HD-HI) in a Phase 3 trial.
  • The filing included data from the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label study of valbenazine in adults with chorea associated with HD.

Worldwide Huntington's Disease Industry to 2029 - A Robust Product Pipeline of Disease-Modifying Treatments is Expected to Drive the Market - ResearchAndMarkets.com

Retrieved on: 
Martedì, Novembre 15, 2022

The "Huntington's Disease Market Analysis by Treatment (Disease-modifying Therapies, Symptomatic Treatment) and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Huntington's Disease Market Analysis by Treatment (Disease-modifying Therapies, Symptomatic Treatment) and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The Hutington's Disease market size is estimated to be USD 475.3 million in 2021 and is expected to witness a CAGR of 21.61% during the forecast period 2022-2029.
  • Ingrezza's expected label expansion for treating chorea associated with Huntington's disease, the high prevalence of HD in Western countries, and a robust product pipeline of disease-modifying treatments is expected to drive the market.
  • However, low success rate in clinical trials is expected to restrain the market growth.

The Worldwide Huntington Disease Treatment Industry is Expected to Reach $1.4 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Martedì, Maggio 10, 2022

The report provides a complete analysis of Global Huntington's Disease Treatment Industry.

Key Points: 
  • The report provides a complete analysis of Global Huntington's Disease Treatment Industry.
  • The global huntington's disease treatment market will reach US$ 1,458.83 Million by 2027, from US$ 405.03 Million in 2021.
  • As per the analysis, Global Huntington's Disease Treatment Market Size is Expanding at a CAGR of 23.81% During 2021-2027.
  • Global Huntington's disease Treatment Industry was US$ 405.03 Million in 2021:
    Based on Treatment Type, the symptomatic treatment segment holds the significant market share.

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022

Retrieved on: 
Venerdì, Aprile 1, 2022

SAN DIEGO, April 1, 2022  /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from the Phase 3 KINECT-HD study, which demonstrated once-daily administration of valbenazine was associated with significant improvement in chorea associated with Huntington disease (HD) compared with placebo. These data (abstract #1199) will be shared as an oral presentation Tuesday, April 5th during the Emerging Science Session at the American Academy of Neurology (AAN) 2022 "Great Neuro Reunion" annual meeting in Seattle, Washington.

Key Points: 
  • The full data results from the Phase 3 KINECT-HD study will be submitted to a peer-reviewed journal later this year.
  • The safety and tolerability of valbenazine in chorea associated with Huntington disease continues to be evaluated in KINECT-HD2, an open-label long-term safety and tolerability study.
  • Neurocrine Biosciences and the Huntington Study Group thank the patients and investigators involved in the KINECT-HD and KINECT-HD2 clinical trials.
  • KINECT-HD2 is an open-label study to evaluate the long-term safety and tolerability of valbenazine in patients with chorea associated withHuntingtondisease (HD).

Huntington's Disease Market Spotlight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Martedì, Gennaio 18, 2022

The "Market Spotlight: Huntington's Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Huntington's Disease" report has been added to ResearchAndMarkets.com's offering.
  • Huntington's disease (HD) is a rare disorder of the central nervous system (CNS) which causes the degeneration of nerve cells.
  • It is an autosomal dominant disease characterized by involuntary choreatic movements, psychiatric and behavioral disturbances, and dementia.
  • The length of the CAG repeats is inversely associated with the age of disease onset - the longer the repeat, the earlier the onset.

DGAP-News: BB Biotech: Gains realized following COVID-19 vaccine booster update enable increases in oncology and CNS

Retrieved on: 
Venerdì, Ottobre 22, 2021

BB Biotech shares showed a return of -3.3% in CHF and -2.0% in EUR for the third quarter of 2021.

Key Points: 
  • BB Biotech shares showed a return of -3.3% in CHF and -2.0% in EUR for the third quarter of 2021.
  • The Investment Team did close its position in Halozyme after 11 years and realized a total profit of USD 235 mn on this investment.
  • The FDA VRBPAC panel voted unanimously to support Moderna COVID-19 vaccine booster dose in certain at risk populations.
  • The quarterly report of BB Biotech AG as at September 30, 2021 can be downloaded at report.bbbiotech.ch/Q321 or www.bbbiotech.com

Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings

Retrieved on: 
Giovedì, Settembre 3, 2020

"We are excited to present new data at this year's Psych Congress and MDS that illustrate the depth and breadth of our movement disorder programs for tardive dyskinesia and Parkinson's disease in clinical research," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.

Key Points: 
  • "We are excited to present new data at this year's Psych Congress and MDS that illustrate the depth and breadth of our movement disorder programs for tardive dyskinesia and Parkinson's disease in clinical research," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons.
  • Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with psychiatric medications such as antipsychotics or antidepressants.
  • The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas.

Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Retrieved on: 
Martedì, Ottobre 1, 2019

In addition, Neurocrine Biosciences will present data on the impact possible TD has on a patient's health-related quality of life from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible TD.

Key Points: 
  • In addition, Neurocrine Biosciences will present data on the impact possible TD has on a patient's health-related quality of life from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible TD.
  • These data will be presented at the 2019 Annual Psych Congress in San Diego, Oct. 3-6, 2019.
  • INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA.
  • These statements include, but are not limited to, statements related to the benefits to be derived by patients from INGREZZA.

Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting

Retrieved on: 
Giovedì, Maggio 16, 2019

SAN DIEGO, May 16, 2019 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD), an involuntary movement disorder.

Key Points: 
  • SAN DIEGO, May 16, 2019 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD), an involuntary movement disorder.
  • These new data analyses will be presented at the American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18-22, 2019.
  • "Many patients with tardive dyskinesia are impacted socially, emotionally and physically, causing them to feel isolated.
  • Neurocrine Biosciences is committed to further understanding the effect of tardive dyskinesia on patients and the long-term benefits of INGREZZA to help alleviate the symptoms."